ArticleChemistry & biology2012
Skipping cancer: small molecule inhibitors of SKP2-mediated p27 degradation.
Article in Chemistry & biology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 16 citations in OpenAlex.
- F-box proteins and cancer: an update from functional and regulatory mechanism to therapeutic clinical prospects.Theranostics · 2020Review
- E47 Governs the MYC-CDKN1B/p27Cellular and molecular gastroenterology and hepatology · 2018Article
- Article
- Identification of cellular proteins interacting with the retroviral restriction factor SAMHD1.Journal of virology · 2014Article
- Small-molecule control of intracellular protein levels through modulation of the ubiquitin proteasome system.Angewandte Chemie (International ed. in English) · 2014Review
- Targeting nucleocytoplasmic transport in cancer therapy.Oncotarget · 2014Review
- Inhibitors of SCF-Skp2/Cks1 E3 ligase block estrogen-induced growth stimulation and degradation of nuclear p27kip1: therapeutic potential for endometrial cancer.Endocrinology · 2013Article
- p27 Stands-up-to-cancer: UPS nuclear service stops.Endocrinology · 2013Article
- Cks1: Structure, Emerging Roles and Implications in Multiple Cancers.Journal of cancer therapy · 2013Article
Corrections and comments
- Comment on
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The cullin-RING ubiquitin ligase, CRL1(SKP2), directing the degradation of the tumor suppressor p27, is a well validated drug target in a wide variety of human cancers. In this issue of Chemistry & Biology, Wu and colleagues describe first-in-class small molecule inhibitors of CRL1(SKP2)-mediated degradation of p27.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.